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Serum magnesium and visfatin levels 
in newly diagnosed non-obese type 2 
diabetes without insulin resistance:  
a cross-sectional study
ABSTRACT
Background. Previous studies demonstrated that type 2 
diabetes (T2D) patients have low serum magnesium 
and high serum levels of visfatin. This study aimed to 
show the relationship between serum levels of insulin, 
visfatin, and magnesium in T2D patients characterized 
by a non-insulin resistance status.
Methods. This was a cross-sectional study conducted in 
the Hawler Medical University, Kurdistan Region, Iraq 
from April 2019 to March 2020. A total number of 130 
T2D patients and 45 healthy subjects were enrolled in 
the study. T2D patients with scores of homeostasis 
model assessment — insulin resistance (HOMA-IR) 
of < 2.5 were included. Serum levels of magnesium, 
visfatin, and glycemic indices, including fasting serum 
glucose, insulin, visfatin, and glycated hemoglobin 
were determined. 
Results. The serum level of visfatin is significantly 
higher in T2D patients than the corresponding values of 
the healthy subjects. Serum magnesium level is signifi-
cantly correlated with the percentage of the glycated 
hemoglobin (Spearman’s correlation factor = 0.184, 
P = 0.036), and a positive significant correlation be-
tween serum insulin and visfatin (r = 0.216, P = 0.014) 
was observed. Multivariate regression analysis of the 
association of fasting serum insulin as a dependent 
variable with serum magnesium and visfatin as inde-
pendent variables showed a non-significant positive 
correlation (r = 0.197, P = 0.082).
Conclusion. Significant low serum levels of magnesium 
and visfatin are observed in non-insulin resistant T2D pa-
tients with a HOMA-IR score of < 2.5. Serum visfatin and 
magnesium levels showed significant correlations with 
glycemic indices. (Clin Diabetol 2020; 10, 1: 123–128)
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Introduction
Several substances have a hypoglycemic effect 
in T2D through their actions as cofactors in releasing 
insulin or increasing the transporting of glucose into 
the cell. The sources of these substances are either 
endogenous (i.e. they naturally occur inside the body) 
or exogenous (i.e. nutritional supplement). Magnesium 
is an example of an exogenous hypoglycemic cation, 
while visfatin is an example of endogenous hypogly-
cemic adipocytokine [1, 2]. 
Magnesium is an intracellular cation that exerts 
multiple functions in the body besides its nutritional 
effect. It acts as a cofactor in the metabolism of car-
bohydrates through its effects on the transporting of 
glucose and releasing of insulin [3, 4]. Low serum ma-
gnesium level in T2D diabetes is a common laboratory 
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investigation, which is associated with complications in-
cluding macroangiopathy, neuropathy retinopathy, and 
nephropathy [5, 6]. In diabetes mellitus, magnesium 
supplementation reduces fasting plasma glucose levels 
by 4.64 mg/dL [7]. The hypoglycemic effect of magne-
sium significantly reduces the score of HOMA-IR by 0.57 
[8]. Visfatin (nicotinamide phosphoribosyltransferase) is 
an adipocytokine synthesized and released by fat cell. 
It has a hypoglycemic effect by binding the insulin-
receptor and increasing the serum free insulin level [9] 
Serum level of visfatin is higher in T2D compared with 
healthy subjects, which is related to the fasting status 
of diabetic patients [10]. High serum visfatin levels 
were observed in T2D patients with insulin resistance, 
obesity, and laboratory evidence of inflammation [11]. 
Previous studies assessed the serum level of visfatin 
and magnesium in T2D patients with insulin resistance 
and diabetic complications. The rationale of this study 
is both magnesium and visfatin can regulate the fast-
ing serum glucose in T2D patient without evidence of 
insulin resistance or diabetic complications. Therefore, 
this study aimed to show the link between the triad 
of fasting serum insulin, magnesium, and visfatin in 
patients without laboratory evidence of insulin resist-
ance with a HOMA-IR of less than 2.5.
Methods
Ethics statement
The institutional ethics and scientific committees of 
Hawler Medical University approved this cross-sectional 
study (Project No. HMU-PH-EC 191105/98). 
Participants
Two hundred twenty patients with newly diag-
nosed T2D and 90 healthy controls (sex- and age-
matched) were recruited from Diabetic Centre in Erbil-
Iraq during the period from April 2019 to March 2020 
in the present study (Fig. 1). The study was conducted 
in Erbil and therefore it included a sample of Kurdish 
population.
Criteria of inclusion
Newly diagnosed T2D patients aged 35–79 years 
were included. T2D was defined by the criteria of the 
American Diabetes Association (fasting blood glucose 
level ≥ 126 mg/dL and/or 2-h postprandial blood glu-
cose level ≥ 200 mg/dL) [12]. 
Criteria of exclusion
Participants treated with insulin or oral antidiabetic 
agents, non-steroidal anti-inflammatory drugs, and nu-
tritional supplements were excluded. Participants with 
endocrinal or bone disorders; renal and liver diseases; 
pregnancy and breastfeeding women were excluded. 
Participants with abnormal laboratory investigations, 
including liver and renal function tests, lipid profile, and 
positive results of inflammatory markers, were excluded 
(Figure 1). The body weight (kg) and the height (m) 
were measured for calculation the body mass index 
(kg/m2), and any participant with a body mass index 
≥ 30 kg/m2 was excluded. A total number of 130 T2D 
patients and 45 healthy subjects were included in the 
laboratory determination of serum insulin, visfatin, and 
magnesium levels. 
laboratory measurements 
A 12-h overnight fasting venous blood samples 
were drawn from all participants, and divided into two 
portions. The first portion was drawn into an EDTA-test 
tube for determination of the HbA1c (Roche/Germany 
Figure 1. Recruitment, inclusion and exclusion of participants
T2D patients (n = 220) and 
healthy controls (n = 90)
Abnormal laboratory ests
T2D patients (n = 50)
Healthy controls (n = 35)
Current drug therapy
T2D patients (n = 9)
Healthy controls (n = 10)
Concomitant illnesses
T2D patients (n = 31)
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Kit). The second portion was drawn into a non-coag-
ulant test tube, left for 30 min for coagulation, and 
then centrifuged for 15 min at 3,000 r.p.m. The sera 
of the patients were separated for determination of 
serum magnesium, glucose, insulin, and visfatin. Serum 
glucose, insulin, and magnesium were determined us-
ing automated analyzer for clinical chemistry analysis 
(Cobas, Roche, and Hitachi, Germany). Visfatin (Elab-
science, USA kit) was determined using enzyme-linked 
immunosorbent assay (ELISA) technology.
Calculation of insulin resistance  
and sensitivity scores
Homeostasis model assessment-insulin  
resistance (HOMA-IR)
HOMA-IR = fasting serum glucose [mmol/L] × 
fasting serum insulin [µU/mL]/22.5 
Previous studies used different cut-off values of 
HOMA-IR for insulin resistance. In our population, 
a cut-off value of ≥ 2.5 was used as indicator of insulin 
resistance based on the clinical studies and was used 
by others [13].
Assessment of b-cell function
HOMA-b = (20 × fasting serum insulin [µU/mL])/ 
/(fasting serum glucose – 3.5). The result is expressed 
as a percentage.
Homeostasis model assessment-insulin  
sensitivity (HOMA-IS)
The value of HOMA-IS is calculated by inverting 
the HOMA-IR.
HOMA-IS = 1/HOMA-IR
Quantitative insulin sensitivity  
check index (Quicki)
This index is simply calculated using the following 
equation:
QUICKI = 1/[log (fasting serum insulin (µU/mL) + 
+ log (fasting serum glucose (mg/dL)]
Statistical analysis
Data were analyzed using SPSS version 20. Stu-
dent’s t test was used to compare differences between 
independent two samples and one-way analysis of 
variance (ANOVA) to compare differences between age 
groups and sex categories. Chi-squared test was used 
to compare the distribution of sex between healthy 
subjects and T2D patients. Spearman’s correlation (r) 
and multivariate regression analysis were calculated to 
show the inter-relationship between the fasting insulin 
level as a dependent variable and serum magnesium 
and visfatin as independent variables. P value of < 0.05 
indicated statistical significance.
Results
Table 1 shows the characteristics of the participants 
enrolled in the study. There are no significant differ-
ences between healthy subjects and T2D patients in 
the mean ± SD of age and distribution of participants 
according to the sex. Significant differences in the 
glycemic indices between healthy subjects and T2D 
patients were observed, and these changes were as-
sociated with significantly higher serum level of visfatin 
and lower serum level of magnesium in T2D patients 
compared with healthy subjects. 
Table 1. Characteristics of the participants
Determinant Healthy subjects (n = 45) Type 2 diabetes patients (n = 130) P value
Sex (Male : Female) 18 : 27 48 : 82 0.714
Age (years) 51.4 ± 9.1 51.7 ± 10.5 0.171
Body weight [kg] 76.0 ± 11.3 76.8 ± 10.9 0.674
Height [m] 1.67 ± 0.15 1.66 ± 0.10 0.615
Body mass index [kg/m2] 27.3 ± 2.3 27.7 ± 1.3 0.157
Fasting serum glucose [mmol/L] 6.07 ± 0.11 ‎9.84 ± 1.23‎ < 0.001
Glycated hemoglobin (%) 5.44 ± 0.07 ‎8.90 ± 0.8‎ < 0.001
HOMA-IR 0.65 ± 0.19 1.71 ± 0.22 < 0.001
Quicki 0.417 ± 0.023 0.353 ± 0.007 0.002
HOMA-b cell (%) 18.78 ± 5.19 12.84 ± 2.77 < 0.001
HOMA-IS (%) 1.673 ± 0.54 0.596 ± 0.081 < 0.001
Serum magnesium [mg/dL] 1.661 ± 0.341 0.979 ± 0.106 < 0.001
Serum visfatin [ng/mL] 30.9 ± 4.0 42.9 ± 2.6 < 0.001
P value was calculated using independent two-sample t-test and Chi-square test. HOMA — homeostatic model assessment; IR — insulin resistance;  
IS — insulin sensitivity; Quicki — quantitative insulin sensitivity check index
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There is no significant difference between males 
and females in the serum levels of glycemic indices, 
visfatin, and magnesium (Table 2). The mean values 
of HOMA-IR and Quicki are 1.71 and 0.353, indicat-
ing the patients in the state of non-insulin resist-
ance. The percentage of the b-cell function is 12.84. 
Figure 2 shows that the mean serum level of visfatin 
is significantly higher in T2D patients than the cor-
responding value of the healthy subjects. Table 3 
shows that there are nonsignificant differences in the 
glycemic indices, serum visfatin, and magnesium level 
between age groups of patients. Serum magnesium 
level is significantly correlated with the percentage 
of the glycated hemoglobin (Spearman correlation 
factor = 0.184, P = 0.036), while there was a positive 
nonsignificant correlation of glycated hemoglobin 
(%) with insulin (r = 0.136, P = 0.123) and visfatin 
(r = 0.001, P = 0.993). Serum insulin significantly posi-
tively correlated with visfatin (r = 0.216, P = 0.014), 
but there are no significant correlations of serum mag-
nesium with insulin or visfatin. Multivariate regression 
analysis of the association of fasting serum insulin as 
Table 2. The mean ± SD of glycemic indices, serum levels of visfatin and magnesium according to the sex distribution
Variables Female (n = 82) Male (n = 48) Total (n = 130) P value
Age (years) 51.2 ± 10.5 52.7 ± 10.5 51.7 ± 10.5 0.448
Serum glucose [mmol] 9.85 ± 1.19 9.81 ± 1.3 9.84 ± 1.23 0.871
Glycated hemoglobin (%) 8.98 ± 0.79 8.76 ± 0.80 8.90 ± 0.8 0.124
Serum insulin [µU] 3.91 ± 0.08 3.90 ± 0.08 3.91 ± 0.08 0.685
HOMA-IR 1.71 ± 0.21 1.70 ± 0.23 1.71 ± 0.22 0.833
Quicki 0.352 ± 0.007 0.353 ± 0.008 0.353 ± 0.007 0.763
HOMA-b cell (%) 12.77 ± 2.64 12.94 ± 3.01 12.84 ± 2.77 0.736
HOMA-IS (%) 0.594 ± 0.078 0.599 ± 0.088 0.596 ± 0.081 0.727
Serum magnesium [mg/dL] 0.990 ± 0.106 0.959 ± 0.103 0.979 ± 0.106 0.105
Serum visfatin [ng/mL] 43.0 ± 2.7 42.6 ± 2.39 42.9 ± 2.6 0.440
P value was calculated using independent two-sample t-test and Chi-square test. HOMA — homeostatic model assessment; IR — insulin resistance;  


































Table 3. The mean ± SD of glycemic indices, serum levels of visfatin and magnesium according to age groups











F value P value
Age (years) 38.1 ± 2.0 45.3 ± 2.6 54.2 ± 2.8 65.2 ± 2.8 73.4 ± 2.8
Serum glucose [mmol] 9.32 ± 1.23 9.91 ± 1.17 10.0 ± 1.23 9.97 ± 1.15 9.66 ± 1.59 1.190 0.319
Glycated hemoglobin (%) 8.97 ± 0.64 8.97 ± 0.79 8.99 ± 0.80 8.45 ± 0.87 8.94 ± 0.88 1.791 0.135
Serum insulin [µU] 3.91 ± 0.07 3.91 ± 0.08 3.91 ± 0.07 3.90 ± 0.08 3.87 ± 0.08 0.784 0.538
HOMA-IR 1.62 ± 0.22 1.72 ± 0.21 1.74 ± 0.22 1.73 ± 0.21 1.66 ± 0.27 1.154 0.334
Quicki 0.356 ± 0.008 0.352 ± 0.007 0.352 ± 0.007 0.352 ± 0.007 0.355 ± 0.009 1.223 0.305
HOMA-b (%) 14.1 ± 3.2 12.62 ± 2.51 12.51 ± 2.67 12.44 ± 2.38 13.43 ± 3.92 1.380 0.245
HOMA-S (%) 0.628 ± 0.091 590 ± 0.075 0.584 ± 0.079 0.587 ± 0.072 0.618 ± 0.108 1.251 0.293
Magnesium [mg/dL] 0.973 ± 0.095 0.982 ± 0.093 0.984 ± 0.113 0.976 ± 0.117 0.957 ± 0.144 0.151 0.962
Visfatin [ng/mL] 42.6 ± 2.3 42.9 ± 2.6 43.2 ± 2.8 42.1 ± 2.1 43.2 ± 2.9 0.640 0.635
P value was calculated using independent two-sample t-test and Chi-square test. HOMA — homeostatic model assessment; IR — insulin resistance;  
IS — insulin sensitivity; Quicki — quantitative insulin sensitivity check Index
Figure 2. Boxplot of serum level of visfatin in T2D patients 
compared with the healthy subjects
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a dependent variable with serum magnesium and vis-
fatin as independent variables showed a nonsignificant 
positive correlation (r = 0.197, F = 2.522, P = 0.082, 
df = 129, R2 = 0.039) that applied to 3.9% of patients 
(Fig. 3). The expected insulin value = 3.702 + (serum 
magnesium × 0.133), t-value 2.128, P = 0.035, while 
the expected insulin value = 3.702 + (serum visfatin 
× 0.002), t-value 0.674, P = 0.502.
Discussion
The results of this study showed that diabetic 
patients have a significantly lower mean value of vis-
fatin than the corresponding mean level of healthy 
subjects, which does not show a significant differ-
ence between sexes and age groups. Serum visfatin 
significantly correlated with the fasting serum insulin, 
but it did not correlate with serum magnesium level. 
A high serum visfatin level in T2D patients with a mean 
value of HOMA-IR less than 2.5 indicates that visfatin is 
a marker of insulin sensitivity. Previous studies showed 
that there is no relationship between serum visfatin level 
and HOMA-IR, and visfatin is not a cause of insulin resist-
ance [14, 15]. A positive significant correlation of serum 
visfatin levels with fasting serum insulin levels indicates 
that there is a relationship between visfatin and insulin 
to reduce the serum level of glucose. Previous studies 
demonstrated that hyperglycemia induced by exogenous 
glucose in healthy subjects elevated the serum levels of 
visfatin, while hyperinsulinemia suppressed the release of 
visfatin [16]. Further study demonstrated the inhibitory 
effect of insulin on the release of visfatin from adipocyte 
in in vitro study [17]. It is important to mention that 
serum visfatin level does not show relation to sex, age, 
body weight, and lipid profile status [17]. The serum level 
of magnesium is below the normal cut-off level (1.7–2.2 
mg/dL) in T2D patients, which is due to deficiency of 
insulin. From the physiological point of view, insulin 
enhances the magnesium uptake by insulin-sensitive tis-
sue, and there is an inverse relationship between serum 
magnesium and insulin levels [4]. Hypomagnesemia is 
frequently observed in one-third of T2D patients, which 
is not related to the age or sex but related to the dura-
tion of diabetes and sometimes associated with diabetic 
complications [5, 18]. The results of this study showed 
a low serum level of magnesium in insulin-sensitive T2D 
patients. Moreover, magnesium supplementation for 
months can improve the serum glucose level, glycated 
hemoglobin, and HOMA-IR in T2D patients [19]. There is 
no relationship between serum visfatin with magnesium 
levels in non-diabetic patients [20]. The results of this 
study showed that the serum level of insulin could be 
evaluated from the serum level of magnesium but not 
the level of visfatin. This observation agreed with previ-
ous studies that reported a decrease of 0.1 mmol/L in 
serum magnesium level carried a risk of development 
of diabetes with a hazard ratio of 1.8 [21]. 
This study highlights important findings that de-
termination of serum visfatin serves as an indicator of 
insulin sensitivity status, while determination of serum 
magnesium can be used to assess the serum insulin 
level in T2D patients with HOMA-IR index below the 
threshold of 2.5. Moreover, this is the first study carried 
on a sample of Kurdish population in Erbil.
limitations of the study
Limitations of the study are the data of T2D pa-
tients with HOMA-IR > 2.5 are not included and we 
did not measure the serum levels of adipocytokines. 
Conclusions
We conclude that T2D patients with HOMA-IR less 
than 2.5 have abnormal values of serum magnesium 
and visfatin, which indicates that the changes in these 
biomarkers are independent to the insulin resistance.
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